Cambiar Investors Reduces Stake in Globus Medical

Institutional investor trims holdings in medical device company by 30% in Q4

Apr. 12, 2026 at 8:37am

Got story updates? Submit your updates here. ›

An extreme close-up of highly detailed, polished metal medical instruments and machinery, representing the technical expertise and manufacturing prowess behind Globus Medical's products.Globus Medical's advanced manufacturing capabilities power its innovative medical devices.Audubon Today

Cambiar Investors LLC, an institutional investment firm, reduced its stake in Globus Medical, Inc. (NYSE: GMED) by 30% in the fourth quarter, according to a recent SEC filing. The firm now owns 81,544 shares of the medical device company's stock, valued at $7.12 million.

Why it matters

Cambiar Investors' move to decrease its position in Globus Medical could signal a shift in sentiment around the company's performance or future prospects among institutional investors. Changes in major shareholder positions can influence a stock's price and trading activity.

The details

According to the filing, Cambiar Investors sold 34,936 shares of Globus Medical during the fourth quarter, reducing its total holdings to 81,544 shares. The firm previously owned 116,480 shares of the medical device company. Globus Medical, headquartered in Audubon, Pennsylvania, develops and markets implantable devices and surgical instruments for spine and orthopedic applications.

  • Cambiar Investors filed the disclosure with the SEC on April 12, 2026.
  • The changes in Cambiar's Globus Medical holdings occurred during the fourth quarter of 2025.

The players

Cambiar Investors LLC

An institutional investment management firm that has reduced its stake in Globus Medical, Inc.

Globus Medical, Inc.

A medical device company specializing in musculoskeletal solutions for spine and orthopedic applications, headquartered in Audubon, Pennsylvania.

Got photos? Submit your photos here. ›

The takeaway

Cambiar Investors' decision to trim its position in Globus Medical could signal a shift in sentiment around the company among institutional investors, potentially impacting the stock's performance and trading activity going forward.